Ascimibis a prescription medicine used to treat adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP),Previously treated Ph+ CML in CP, Ph+ CML in CP with the T315I mutation.
Ascimibis a targeted cancer therapy that blocks the BCR-ABL1 fusion protein in Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML).
Ascimibis a targeted therapy called a STAMP inhibitor. It works by blocking the BCR‑ABL1 protein in leukemia cells, not by stimulating the immune system.
Ascimib is a generic version of Scemblix which is Asciminib indicated for (Ph+ CML) in chronic phase (CP).
As a Least Developed Country (LDC), Bangladesh received a special waiver under the WTO’s TRIPS Agreement (Trade-Related Aspects of Intellectual Property Rights) until 2033. This allows Bangladesh to produce generic versions of patented drugs without paying royalties, significantly reducing manufacturing costs.
Ascimib tablets should be taken orally twice daily without food, following your healthcare provider’s exact instructions.
No. As a commitment to patient affordability, Everest Pharmaceuticals Ltd. proudly introduces Ascimib, the generic versionofScemblix (Asciminib). This medication is now accessible to patients worldwide at a more affordable price. Contact us to learn more about availability and purchasing options.
This medicine may cause serious infections, including low blood cell counts, pancreas problems, high blood pressure, allergic reaction. Check with your doctor if you have symptomssuch as
muscle, bone, or joint pain, rash, tiredness, diarrhea etc.
